Previous 10 | Next 10 |
DUBLIN , May 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 31, 2020 . Revenue for the first quarter 2020 was $19.9 million . Operating loss was $72.5 ...
DUBLIN , April 28, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and prov...
Theravance Biopharma (NASDAQ: TBPH ) doses first healthy volunteer in Phase 1 study of TD-0903 . TD-0903 is a lung-selective, nebulized Janus kinase inhibitor (JAKi) in development for the treatment of hospitalized patients with Acute Lung Injury (ALI) caused by COVID-19. More news on: ...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 23, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-select...
Manuscript Provides Comprehensive Summary of Positive Results from Clinical and Preclinical TD-1473 Studies Conducted to Date Gut-Selective Pan-JAK Inhibition with TD-1473 Has Demonstrated Minimal Systemic Drug Exposure, Local Target Engagement and Trends Toward Reduced Markers of Ulcer...
The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company's (NYSE: BHVN ) migraine med vazegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, in COVID-19 patients with pulmonary complications who ne...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 9, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selecti...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q4 2019 Earnings Call Feb 24, 2020 , 5:00 p.m. ET Operator Continue reading
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2019 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update af...